These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 26542336)

  • 41. Cardiology patient page. Breast cancer chemotherapy and your heart.
    Unitt C; Montazeri K; Tolaney S; Moslehi J
    Circulation; 2014 Jun; 129(25):e680-2. PubMed ID: 24958758
    [No Abstract]   [Full Text] [Related]  

  • 42. [Monitoring of cardiac damage in cancer patients treated with cardiotoxic drugs].
    Tarantini L; Faggiano P; Barni S; Gori S
    G Ital Cardiol (Rome); 2013 Jun; 14(6):416-23. PubMed ID: 23748538
    [TBL] [Abstract][Full Text] [Related]  

  • 43. President's Message: contrast echocardiography: moving from controversy to consensus.
    Zoghbi WA
    J Am Soc Echocardiogr; 2008 Sep; 21(9):A25-6. PubMed ID: 18765170
    [No Abstract]   [Full Text] [Related]  

  • 44. Newest echocardiographic techniques for the detection of cardiotoxicity and heart failure during chemotherapy.
    Sawaya H; Plana JC; Scherrer-Crosbie M
    Heart Fail Clin; 2011 Jul; 7(3):313-21. PubMed ID: 21749883
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Introduction to the Cardio-Oncology Miniseries.
    Davidoff R; Fifer M; Francis S
    Circulation; 2015 Nov; 132(19):1834. PubMed ID: 26553712
    [No Abstract]   [Full Text] [Related]  

  • 46. Subclinical anthracycline- and trastuzumab-induced cardiotoxicity in the long-term follow-up of asymptomatic breast cancer survivors: a speckle tracking echocardiographic study.
    Ho E; Brown A; Barrett P; Morgan RB; King G; Kennedy MJ; Murphy RT
    Heart; 2010 May; 96(9):701-7. PubMed ID: 20424152
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Overview and historical development of dexrazoxane.
    Hellmann K
    Semin Oncol; 1998 Aug; 25(4 Suppl 10):48-54. PubMed ID: 9768824
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Therapeutic drug monitoring in oncology: does it have a future?
    McMahon G; O'Connor R
    Bioanalysis; 2009 Jun; 1(3):507-11. PubMed ID: 21083145
    [No Abstract]   [Full Text] [Related]  

  • 49. Relationship of promising methods in the detection of anthracycline-induced cardiotoxicity in breast cancer patients.
    Bulten BF; Verberne HJ; Bellersen L; Oyen WJ; Sabaté-Llobera A; Mavinkurve-Groothuis AM; Kapusta L; van Laarhoven HW; de Geus-Oei LF
    Cancer Chemother Pharmacol; 2015 Nov; 76(5):957-67. PubMed ID: 26400150
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Heart health after breast cancer.
    Johns Hopkins Med Lett Health After 50; 2009 Dec; 21(10):1-2. PubMed ID: 20020542
    [No Abstract]   [Full Text] [Related]  

  • 51. Caution for interstitial lung disease as a cause of CA 15-3 rise in advanced breast cancer patients treated with everolimus.
    Willemsen AE; Grutters JC; Gerritsen WR; Tol J; van Herpen CM
    Int J Cancer; 2014 Aug; 135(4):1007. PubMed ID: 24415627
    [No Abstract]   [Full Text] [Related]  

  • 52. Cardiac risks in multimodal breast cancer treatment.
    Budach W
    Strahlenther Onkol; 2007 Dec; 183 Spec No 2():9-10. PubMed ID: 18166997
    [No Abstract]   [Full Text] [Related]  

  • 53. Neoadjuvant trastuzumab for breast cancer. Better to stick with proven treatments.
    Prescrire Int; 2013 Feb; 22(135):39. PubMed ID: 23444499
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Cardioncology, oncocardiology. Are we barking up the wrong tree?
    Lestuzzi C
    Int J Cardiol; 2013 Jul; 167(2):307-9. PubMed ID: 23669115
    [No Abstract]   [Full Text] [Related]  

  • 55. Anthracycline cardiotoxicity in breast cancer patients: synergism with trastuzumab and taxanes.
    Gianni L; Salvatorelli E; Minotti G
    Cardiovasc Toxicol; 2007; 7(2):67-71. PubMed ID: 17652806
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Myocardial Protection During Cardiotoxic Chemotherapy.
    Witteles RM; Bosch X
    Circulation; 2015 Nov; 132(19):1835-45. PubMed ID: 26553713
    [No Abstract]   [Full Text] [Related]  

  • 57. Cardio-oncology in multiple myeloma: is it time for a specific focus?
    Mancuso S; Carlisi M; Sarocchi M; Napolitano M; Siragusa S
    Leuk Lymphoma; 2018 Jul; 59(7):1764-1766. PubMed ID: 29087234
    [No Abstract]   [Full Text] [Related]  

  • 58. Doxorubicin/paclitaxel combination does not expose breast cancer patients to excessive cardiac risk.
    Oncology (Williston Park); 2001 Jul; 15(7):830. PubMed ID: 11499684
    [No Abstract]   [Full Text] [Related]  

  • 59. Blocking breast cancer relapses.
    Johns Hopkins Med Lett Health After 50; 2006 Feb; 17(12):1-2. PubMed ID: 17115471
    [No Abstract]   [Full Text] [Related]  

  • 60. Trastuzumab versus lapatinib: the cardiac side of the story.
    Azim H; Azim HA; Escudier B
    Cancer Treat Rev; 2009 Nov; 35(7):633-8. PubMed ID: 19640652
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.